Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 6, 2014, Pages 1636-1644

  Chiron, Marielle ^a   Bagley, Rebecca G ^b   Pollard, Jack ^b   Mankoo, Parminder K ^b   Henry, Christophe ^a   Vincent, Loïc ^a   Geslin, Catherine ^a   Baltes, Nina ^c   Bergstrom, Donald A ^b  

^a SANOFI   (France)

^b Sanofi Oncology   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; VASCULOTROPIN A; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; STROMA; XENOGRAFT; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG POTENTIATION; DRUG SCREENING; GENETICS; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PREGNANCY PROTEINS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902678443     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0753     Document Type: Article

References (50)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86. (Pubitemid 46505878)
2. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9 (suppl 1):2-10. (Pubitemid 38747842)
3. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 2005;109:227-41. (Pubitemid 41337127)
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76. (Pubitemid 36749215)
5. Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M, Filho AL. Clinicopathological correlation and prognostic signi ficance of VEGFA, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics 2013;10:55-67.
6. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18.
7. Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of bevacizumab (Avastin) on survival in metastatic solid tumors - a meta-analysis and systematic review. PLoS ONE 2013;8:e51780.
8. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80. (Pubitemid 35266299)
9. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 1991;88:9267-71. (Pubitemid 21915612)
10. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 2008;11:215-21.
11. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 2002; 115:2559-67. (Pubitemid 34778073)
12. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83. (Pubitemid 32448325)
13. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8:942-56.
14. Escudero-Esparza A, Martin TA, Davies ML, Jiang WG. PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. Cancer Genomics Proteomics 2009;6:239-46.
15. Escudero-Esparza A, Martin TA, Douglas-Jones A, Mansel RE, Jiang WG. PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance. Oncol Rep 2010;23:537-44.
16. Woo IS, Park MJ, Byun JH, Hong YS, Lee KS, Park YS, et al. Expression of placental growth factor gene in lung cancer. Tumour Biol 2004;25:1-6. (Pubitemid 38822764)
17. Maae E, Olsen DA, Steffensen KD, Jakobsen EH, Brandslund I, Sørensen FB, et al. Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat 2012;133:257-65.
18. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010;28:453-9.
19. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009;27:3020-6.
20. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM,et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8.
21. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman J, Lin E, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS ONE 2013;8:e77117.
22. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumor without affecting healthy vessels. Cell 2007;131:463-75. (Pubitemid 350007692)
23. Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K, et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010;141:166-77.
24. Yao J, Wu X, Zhuang G, Kasman IM, Vogt T, Phan V, et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A 2011;108:11590-5.
25. Frank NY, Schatton T, Kim S, Zhan Q, Wilson BJ, Ma J, et al. VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res 2011;71:1474-85.
26. Lee Y-J, Karl DL, Maduekwe UN, Rothrock C, Ryeom S, D'Amore PA, et al. Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Res 2010;70:8357-67.
27. Tol J, Punk CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 2010;32:437-53.
28. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Comm 2005;333:328-35. (Pubitemid 40848295)
29. Avastin (bevacizumab) prescribing information. South San Francisco, CA: Genentech, Inc.; 2013.
30. Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2012;11:1-13.
31. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12.
32. Stivarga (regorafenib) prescribing information. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2013.
33. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499-506.
34. Zaltrap (ziv-aflibercept) prescribing information. Bridgewater, NJ: Regeneron Pharmaceuticals, Inc./sanofi-aventis U.S. LLC; 2012.
35. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-8. (Pubitemid 34920936)
36. Papadopoulos N, Martin J, Ruan J, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85.
37. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012;9:338-50.
38. Juline S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 2012;18:5314-28.
39. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 2007;104:18363-70. (Pubitemid 350210713)
40. Sawada T, Yamamoto E, Suzuki H, Nojima M, Maruyama R, Shioi Y, et al. Association between genomic alterations and metastatic behavior of colorectal cancer identifi ed by array-based comparative genomic hybridization. Genes Chromosomes Cancer 2013;52:140-9.
41. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-61.
42. Miranda E, Bianchi P, Destro A, Morenghi E, Malesci A, Santoro A, et al. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer 2013;119:266-76.
43. Smits KM, Cleven AHG, Weijenberg MP, Hughes LAE, Herman JG, de Bruïne AP, et al. Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. Pharmacogenomics 2008;9:1903-16.
44. Valence S, Guerif S, Jouannot E, Vrignaud P, Vincent L, Dib C, et al. Influence of tumor genotype on a flibercept (VEGF Trap) antitumor activity in preclinical tumors. Mol Cancer Ther 2011;10 (suppl; abstr C162):1.
45. Pechańska P, Becker M, Mayr T, Hinzmann B, Adams HP, Klaman I, et al. Mutation status of KRAS, BRAF, PIK3CA and expression level of AREG and EREG identify responders to cetuximab in a large panel of patient derived colorectal carcinoma xenografts of all four UICC stages. J Cancer Ther 2013;4:678-93.
46. Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: in vitro biological studies. Biochem Biophys Res Commun 2011;408:276-81.
47. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011;104:1262-9.
48. American Type Culture Collection (ATCC). Passage number effects in cell lines. ATCC Tech Bulletin [Internet] No. 7. 2010. Available from: http://www.atcc.org/~/media/PDFs/Technical%20Bulletins/tb07.ashx.
49. Fiebig HH, Burger AM. Patient-derived tumor models and explants. In: Teicher B, editor. Tumor models in cancer research. 2nd ed. Totowa, NJ: Humana Press Inc.; 2011. p. 167-93.
50. Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, Bilancia D. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother Pharmacol 2013;71:257-64.